While there are shared principles across development programs, Barr noted that the nuances within immunology, ophthalmology, or chronic care studies can determine whether a trial succeeds or fails.

The emergence of AI and biosensors offers a chance to address inefficiencies in drug development.

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...

Real-world studies assess treatment effectiveness and patient experience beyond clinical trial settings, considering broader patient populations. Clinical trials have stricter enrollment criteria, ...

Data sharing and collaboration among experts is a time-tested guide to help practicing clinicians abide by the Food and Drug Administration’s (FDA’s) black box warning. Practicing clinicians, whether ...

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of ...

The most important benefit of participating in a clinical trial is that patients get early access to potentially new and successful treatments or screenings before the general public. (Karmanos Cancer ...

AUSTIN, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (PSTV) (Nasdaq: PSTV) (“Plus” or the “Company”), will present data from ...